Stock Track | Hims & Hers Health Plunges 13.49% in Post-Market After Q1 Earnings Miss, Swing to Loss

Stock Track

May 12

Hims & Hers Health Inc. (HIMS) experienced a significant post-market plunge of 13.49% on Monday, as investors reacted negatively to the company's first-quarter 2026 financial results.

The telehealth company reported a quarterly loss of $0.40 per share, dramatically missing analyst expectations for a profit. Revenue for the quarter came in at $608.1 million, falling short of consensus estimates. More critically, the company swung to a net loss of $92.1 million, compared to net income in the same period last year.

The earnings miss was driven by several factors, including approximately $33 million in restructuring costs tied to write-downs of its compounded GLP-1 supply chain. This followed a strategic pivot to focus on selling FDA-approved branded weight-loss medications, which increased expenses. The company also lowered its full-year adjusted EBITDA guidance, and its Chief Financial Officer indicated a return to profitability is expected in 2027.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/1141591481"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1141591481\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1141591481?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-12 08:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1141591481","market":"nz","top_or_hot":-1,"title":"Stock Track | Hims & Hers Health Plunges 13.49% in Post-Market After Q1 Earnings Miss, Swing to Loss","media":"Stock Track","content":"<p>Hims & Hers Health Inc. (HIMS) experienced a significant post-market plunge of 13.49% on Monday, as investors reacted negatively to the company's first-quarter 2026 financial results.</p><p>The telehealth company reported a quarterly loss of $0.40 per share, dramatically missing analyst expectations for a profit. Revenue for the quarter came in at $608.1 million, falling short of consensus estimates. More critically, the company swung to a net loss of $92.1 million, compared to net income in the same period last year.</p><p>The earnings miss was driven by several factors, including approximately $33 million in restructuring costs tied to write-downs of its compounded GLP-1 supply chain. This followed a strategic pivot to focus on selling FDA-approved branded weight-loss medications, which increased expenses. The company also lowered its full-year adjusted EBITDA guidance, and its Chief Financial Officer indicated a return to profitability is expected in 2027.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Hims & Hers Health Plunges 13.49% in Post-Market After Q1 Earnings Miss, Swing to Loss</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Hims & Hers Health Plunges 13.49% in Post-Market After Q1 Earnings Miss, Swing to Loss\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-05-12 08:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Hims & Hers Health Inc. (HIMS) experienced a significant post-market plunge of 13.49% on Monday, as investors reacted negatively to the company's first-quarter 2026 financial results.</p><p>The telehealth company reported a quarterly loss of $0.40 per share, dramatically missing analyst expectations for a profit. Revenue for the quarter came in at $608.1 million, falling short of consensus estimates. More critically, the company swung to a net loss of $92.1 million, compared to net income in the same period last year.</p><p>The earnings miss was driven by several factors, including approximately $33 million in restructuring costs tied to write-downs of its compounded GLP-1 supply chain. This followed a strategic pivot to focus on selling FDA-approved branded weight-loss medications, which increased expenses. The company also lowered its full-year adjusted EBITDA guidance, and its Chief Financial Officer indicated a return to profitability is expected in 2027.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HIMS","symbol_name":"Hims & Hers Health Inc.","start_time":0,"source_url":"","article_id":"1141591481","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1141591481","pubTimestamp":1778544072,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Hims & Hers Health Inc. (HIMS) experienced a significant post-market plunge of 13.49% on Monday, as investors reacted negatively to the company's first-quarter 2026 financial results.The telehealth...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HIMS":"Hims & Hers Health Inc."},"translate_title":"个股追踪|Hims&Hers Health在Q1盈利未达预期后盘后暴跌13.49%，转为亏损","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HIMS":1},"content_text":"Hims & Hers Health Inc. (HIMS) experienced a significant post-market plunge of 13.49% on Monday, as investors reacted negatively to the company's first-quarter 2026 financial results.The telehealth company reported a quarterly loss of $0.40 per share, dramatically missing analyst expectations for a profit. Revenue for the quarter came in at $608.1 million, falling short of consensus estimates. More critically, the company swung to a net loss of $92.1 million, compared to net income in the same period last year.The earnings miss was driven by several factors, including approximately $33 million in restructuring costs tied to write-downs of its compounded GLP-1 supply chain. This followed a strategic pivot to focus on selling FDA-approved branded weight-loss medications, which increased expenses. The company also lowered its full-year adjusted EBITDA guidance, and its Chief Financial Officer indicated a return to profitability is expected in 2027.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}